Home/Pipeline/IML-106

IML-106

HIV Infection

Pre-clinicalActive

Key Facts

Indication

HIV Infection

Phase

Pre-clinical

Status

Active

Company

Immunologik

About Immunologik

ImmunoLogik is a private, preclinical-stage biotech developing host-targeted antivirals for HIV and coronaviruses. Its lead candidates, IML-106 for HIV and IML-206 for SARS-CoV-2/other coronaviruses, aim to block essential cellular pathways used by viruses for replication, potentially reducing the risk of drug resistance. The company leverages strong academic ties, notably with the University Hospital Erlangen, and is supported by the strategic and operational expertise of the Athenion Group. It is currently pre-revenue and focused on advancing its pipeline through preclinical development.

View full company profile

Therapeutic Areas

Infectious Disease Immunology

Other HIV Infection Drugs

Drug	Company	Phase	Status
HIV Self Test	Atomo Diagnostics	Commercial	Active
HIV Treatment Portfolio	MSD	Commercial	Active
Maraviroc Tablets	i3 Pharmaceuticals	Approved	Active
HIV Antibodies	Polymun Scientific	Pre-clinical	Active
HIV Program	Vichem Chemie Research	Pre-clinical	Active
Abacavir	Laboratorio Elea Phoenix	Commercial	Active